natgillin/translations-raw huggingface dataset:
The concentration of topotecan in the 5 ml vial is higher (3 mg/ml) than with other topotecan products. 
Koncentracija topotekana v 5 ml viali je večja (3 mg/ml) kot pri drugih zdravilih s topotekanom.
The concentration of topotecan is higher (3 mg/ml) than with other topotecan products. 
Koncentracija topotekana je večja (3 mg/ml) kot pri drugih zdravilih s topotekanom.
Median (95 % C.I) Hazard ratio (95 % C.I.) 
Mediana vrednost (95 % interval zaupanja) Razmerje tveganja (95 % interval zaupanja) Log rank p-vrednost
Severe (grade 3 or 4) nausea, vomiting, diarrhoea and mucositis incidence was 4, 3, 2 and 1 % respectively. 
Hude oblike (3. ali 4. stopnje) motenj so ugotavljali v naslednjih odstotkih: navzea 4 %, bruhanje 3 %, driska 2 %, mukozitis 1 %.
Cervical Carcinoma 
Karcinom materničnega vratu
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE
Common: hypersensitivity reaction including rash Rare: anaphylactic reaction, angioedema, urticaria 
Redki: anafilaktična reakcija, angioedem, urtikarija.
− already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils < 1.5 x 109/l and/or a platelet count of < 100 x 109/l. 
- bolnicah, ki dojijo (glejte poglavje 4.6); - bolnikih, ki imajo hudo depresijo kostnega mozga že pred začetkom prvega cikla, kar je razvidno iz izhodiščnega števila nevtrofilcev < 1,5 x 109/l in/ali števila trombocitov
Hydrochloric acid (E507) (for pH adjustment) Water for injections 
6.1 Seznam pomožnih snovi klorovodikova kislina (E507) (za uravnavanje pH) voda za injekcije
The concentration of topotecan in the 1 ml vial is higher (3 mg/ml) than with other topotecan products. 
Koncentracija topotekana v 1 ml viali je večja (3 mg/ml) kot pri drugih zdravilih s topotekanom.
Common: malaise 
Pogosti: pruritus.
To be diluted before use. 
Pred uporabo razredčiti.
One Phase 2 study (Study 065) and one Phase 3 study (Study 396) were conducted to evaluate the efficacy of oral topotecan versus intravenous topotecan in patients who had relapsed ≥ 90 days after completion of one prior regimen of chemotherapy (see Table 1). 
Za oceno učinkovitosti peroralnega topotekana v primerjavi z intravenskim topotekanom pri bolnikih, ki se jim je pojavil relaps ≥ 90 dni po koncu ene predhodne sheme kemoterapije, sta bili narejeni ena študija 2. faze (študija 065) in ena študija 3. faze (študija 396) (glejte preglednico 1).
Cisplatin 50mg/m d.1 + Topotecan 0.75mg/m2 dx3 q21 
topotekan 2/dan x 3 0,75 mg/m na 21 dni
Hazard ratio (95 % CI) Response rate (%) 
Delež odziva (%) (95 % IZ)
2 Fatalities due to sepsis have been reported in patients treated with topotecan (see section 4.4) 
2 Pri bolnikih, ki so se zdravili s topotekanom, so poročali o smrti zaradi sepse (glejte poglavje
Very common: febrile neutropenia, neutropenia (see Gastrointestinal disorders), 
Zelo pogosti: nevtropenija s sočasno povišano telesno temperaturo, nevtropenija (glejte Bolezni prebavil), trombocitopenija, anemija, levkopenija.
How Topotecan Eagle is given Topotecan Eagle is normally given by a doctor or nurse: - as a drip (infusion) for about 30 minutes - usually into your arm. 
Kako se zdravilo Topotekan Eagle daje Zdravilo Topotekan Eagle običajno daje zdravnik ali medicinska sestra:
This medicine is not recommended if you have severe liver problems; - if you have lung problems, or if you have had lung problems before from using other medicines or radiation. 
• če imate težave s pljuči ali če ste že imeli težave s pljuči zaradi drugih zdravil ali obsevanja.
Topotecan should not be re-administered unless the neutrophil count is ≥ 1 x 109/l, the platelet count is ≥ 100 x 109/l, and the haemoglobin level is ≥ 9 g/dl (after transfusion if necessary). 
Pred naslednjo uporabo topotekana mora biti število nevtrofilcev  1 x 109/l, število trombocitov  100 x 109/l, vrednost hemoglobina pa  9 g/dl (po transfuziji, če je le-ta potrebna).
Oral and intravenous topotecan were associated with similar symptom palliation in patients with relapsed sensitive SCLC in patient selfreports on an unblinded symptom scale assessment in each of these two studies. 
Na podlagi neslepljene ocene lestvice simptomov po navedbi bolnikov samih v obeh teh študijah sta peroralni in intravenski topotekan pri bolnikih z relapsom občutljivega drobnoceličnega pljučnega raka dosegla podobno ublažitev simptomov.
Topotecan/Cisplatin 
Peroralni topotekan
A. 
Ena
Cisplatin is administered as an intravenous infusion on day 1 at a dose of 50 mg/m2/day and following the topotecan dose. 
Bolnica ga 1., 2. in 3. dan prejme v obliki 30minutne intravenske infuzije enkrat na dan. 1. dan po prejemu odmerka topotekana bolnica prejme še intravensko infuzijo cisplatina v odmerku 50 mg/m2/dan.
- if you are breast-feeding. 
• če imate težave z jetri.
Insufficient data are available to make a recommendation for patients with a creatinine clearance < 20 ml/min. 
Samostojno zdravljenje (drobnocelični pljučni karcinom) Za zdravljenje bolnikov z očistkom kreatinina < 20 ml/min ne moremo priporočiti ustreznih odmerkov, saj imamo premalo izkušenj.
Small cell lung cancer - The usual dose is 1.5 mg of the medicine for each square meter of your body. 
• običajni odmerek je 1,5 mg zdravila na kvadratni meter telesne površine;
NAME OF THE MEDICINAL PRODUCT Topotecan Eagle 3 mg/1 ml concentrate for solution for infusion 
IME ZDRAVILA Topotekan Eagle 3 mg/1 ml koncentrat za raztopino za infundiranje
− are breast feeding (see section 4.6) 
(glejte poglavje 4.5).
Median survival (weeks) 
Mediano preživetje (tedni) (95 % IZ)
Hydrochloric acid (E507) Water for injections 
6.1 Seznam pomožnih snovi klorovodikova kislina (E507) (za uravnanje pH) voda za injekcije
NAME OF THE MEDICINAL PRODUCT Topotecan Eagle 15 mg/5 ml concentrate for solution for infusion 
IME ZDRAVILA Topotekan Eagle 15 mg/5 ml koncentrat za raztopino za infundiranje
For more information about cisplatin, please read its Package Leaflet. 
Več informacij o cisplatinu najdete v njegovem navodilu za uporabo.
Topotecan Eagle 15 mg/5 ml concentrate for solution for infusion topotecan 
Topotekan Eagle 15 mg/5 ml koncentrat za raztopino za infundiranje topotekan
Tell your doctor immediately if you notice any of the following serious side effects. 
Če opazite katerega od naslednjih resnih neželenih učinkov, nemudoma obvestite zdravnika.
For reduced dose '1.0 mg/m2' 
Za zmanjšani odmerek „1,0 mg/m
Topotecan Eagle 3 mg/1 ml concentrate for solution for infusion Topotecan 
Topotekan Eagle 3 mg/1 ml koncentrat za raztopino za infundiranje topotekan
In another randomised phase III trial which compared intravenous topotecan to cyclophosphamide, Adriamycin (doxorubicin) and vincristine (CAV) in patients with relapsed, sensitive SCLC, the overall response rate was 24.3 % for topotecan compared to 18.3 % for the CAV group. 
V drugi randomizirani raziskavi III. faze so primerjali intravenski topotekan s ciklofosfamidom, Adriamycinom (doksorubicin) in vinkristinom (CAV).
Cytotoxic Notice concentration or life-threatening overdose may occur. 
Citotoksično zdravilo Upoštevajte koncentracijo, sicer lahko pride do življenjsko nevarnega prevelikega odmerjanja.
In patients (n = 39) with recurrence within 180 days after chemoradiotherapy with cisplatin, the median survival in the topotecan plus cisplatin arm was 4.6 months (95 % C.I. 
Pri bolnicah (n = 39) s ponovitvijo v 180 dneh po kemoradioterapiji s cisplatinom je bila mediana vrednost preživetja v skupini, ki je prejemala topotekan in cisplatin, 4,6 meseca (95 % interval zaupanja: 2,6; 6,1), v skupini, ki je prejemala cisplatin, pa 4,5 meseca (95 % intervala zaupanja: 2,9; 9,6), razmerje tveganja 1,15 (0,59; 2,23).
Topotecan is contraindicated in patients who 
Topotekan je kontraindiciran pri: - bolnikih, ki imajo v anamnezi hudo preobčutljivostno reakcijo na zdravilno učinkovino ali
Common - mild allergic reactions (including rash) - yellow skin (jaundice) caused by liver problems - itching (pruritus) 
• rumeno obarvanje kože (zlatenica) zaradi težav z jetri;
It is a type of chemotherapy. 
• ponovitve drobnoceličnega pljučnega raka po kemoterapiji.
Concentrate for solution for infusion (3 mg/ml) 
klorovodikova kislina (E507) voda za injekcije koncentrat za raztopino za infundiranje (3 mg/ml)
The recommended dose of topotecan is 0.75 mg/m2/day administered as 30 minute intravenous infusion daily on days 1, 2 and 3. 
Priporočeni odmerek topotekana je 0,75 mg/m2/dan.
Median (95 % C.I.) 
Mediana vrednost (95 % interval zaupanja)
: 4.9, 9.5) for the cisplatin arm with an hazard ratio of 0.75 (0.49, 1.16). 
Pri bolnicah (n = 102) s ponovitvijo po 180 dneh je bila mediana vrednost preživetja v skupini, ki je prejemala topotekan in cisplatin, 9,9 meseca (95 % interval zaupanja: 7; 12,6) v skupini, ki je prejemala cisplatin, pa 6,3 meseca (95 % interval zaupanja: 4,9; 9,5), razmerje tveganja 0,75 (0,49; 1,16).
Read the leaflet for the shelf life of the diluted product. 
Za rok uporabnosti razredčenega zdravila glejte priloženo navodilo.
Topotecan Eagle 3 mg/1 ml concentrate for solution for infusion topotecan 
NAVODILO ZA UPORABO Topotekan Eagle 3 mg/1 ml koncentrat za raztopino za infundiranje topotekan
Topotecan Eagle 15 mg/5 ml concentrate for solution for infusion Topotecan 
NAVODILO ZA UPORABO Topotekan Eagle 15 mg/5 ml koncentrat za raztopino za infundiranje topotekan
This medicine is not recommended if you have severe kidney problems; - if you have liver problems. 
Zdravila Topotekan Eagle se ne priporoča v primeru hudih težav z ledvicami;
NAME OF THE MEDICINAL PRODUCT Topotecan Eagle 3 mg/1 ml concentrate for solution for infusion topotecan 
IME ZDRAVILA IN POT(I) UPORABE Topotekan Eagle 3 mg/1 ml koncentrat za raztopino za infundiranje topotekan i.v.
You should stop breast-feeding before starting treatment with 
Pred začetkom zdravljenja z zdravilom Topotekan Eagle morate prekiniti z
NAME OF THE MEDICINAL PRODUCT Topotecan Eagle 15 mg/5 ml concentrate for solution for infusion topotecan 
IME ZDRAVILA IN POT(I) UPORABE Topotekan Eagle 15 mg/5 ml koncentrat za raztopino za infundiranje topotekan i.v.
The information provided in the Physician Leaflet should provide information on dose reduction, discontinuation and wash out procedures in the event of raised ALT. 
Informacije v navodilu za zdravnika morajo vsebovati podatke o prilagajanju odmerka, prenehanju zdravljenja in postopkih za odstranitev v primeru povišanih vrednosti ALT.
• The identified risk of synergistic hepato- or haematotoxicity associated with combination therapy with another Disease-Modifying Antirheumatic Drug (e.g. methotrexate) 
• O ugotovljenem tveganju za sinergistično hepato ali hematotoksičnost v povezavi s kombinirano terapijo z drugimi imunomodulirajočimi protirevmatičnimi zdravili (diseasemodifying antirheumatic drug (DMARD) (na primer metotreksat).
The Member States shall ensure that the Marketing Authorisation Holder (MAH) provides physicians who are expected to prescribe/use Repso with a physician educational pack containing the following: 
Imetnik dovoljenja za promet bo poskrbel, da bodo vsi zdravniki, ki nameravajo predpisovati zdravilo Repso dobili izobraževalno gradivo, ki vsebuje:
• That there is a risk of severe liver injury and so regular measurement of ALT (SGPT) levels to monitor liver function is important. 
• Da obstaja tveganje za hudo jetrno poškodbo in je zato pomembno redno spremljanje jetrne funkcije z meritvami vrednosti ALT (SGPT).
• inactivated polioviruses; 
• inaktivirane polioviruse;
The choice of booster vaccine depends on official recommendations. 
Izbira poživitvenega cepiva je odvisna od uradnih priporočil.
The main measure of effectiveness was the production of protective antibodies. 
Glavno merilo učinkovitosti je bila tvorba zaščitnih protiteles.
• parts of the hepatitis B virus; 
• dele virusa hepatitisa B;
The full EPAR for Infanrix hexa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Infanrix hexa je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Vaccines work by ‘teaching' the immune system (the body's natural defences) to defend the body against the infections. 
Cepiva delujejo tako, da imunski sistem (naravni obrambni mehanizem telesa) „naučijo“, kako naj brani telo pred okužbami.
This is a summary of the European public assessment report (EPAR) for Infanrix hexa. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Infanrix hexa.
The European Medicines Agency therefore decided that Infanrix hexa's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Infanrix hexa večje od z njim povezanih tveganj, in priporočila, da se zanj izda dovoljenje za promet.
Infanrix hexa has been studied in nine studies, involving a total of almost 5,000 children aged between 6 weeks and 2 years. 
Zdravilo Infanrix hexa so raziskali v devetih študijah, v katere je bilo skupaj vključenih skoraj 5 000 otrok, starih od šest tednov do dveh let.
• toxoids (chemically weakened toxins) from diphtheria and tetanus; 
• toksoide (kemično oslabljene toksine) davice in tetanusa;
The European Commission granted a marketing authorisation valid throughout the EU for Infanrix hexa on 23 October 2000. 
Evropska komisija je dovoljenje za promet z zdravilom Infanrix hexa, veljavno po vsej Evropski uniji, izdala 23. oktobra 2000.
What measures are being taken to ensure the safe and effective use of Infanrix hexa? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Infanrix hexa?
The vaccination schedule for Infanrix hexa is a course of 2 or 3 doses, given at least 1 month apart, according to official recommendations, usually in the first 6 months of life. 
Program cepljenja za zdravilo Infanrix hexa sta 2 ali 3 odmerki, ki se dajo v razmaku vsaj enega meseca, v skladu z uradnimi priporočili, običajno v prvih šestih mesecih življenja.
When a child is given the vaccine, the immune system recognises the parts of the bacteria and viruses in the vaccine as ‘foreign' and makes antibodies against them. 
Ko otrok prejme cepivo, imunski sistem prepozna dele bakterij in virusov v cepivu kot „tujke“ in proti njim razvije protitelesa.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Infanrix hexa have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Infanrix hexa upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Other information about Infanrix hexa: 
Druge informacije o zdravilu Infanrix hexa:
Infanrix hexa must not be used in infants who have had encephalopathy (brain disease) of unknown cause within 7 days of receiving a pertussis vaccine. 
Cepivo Infanrix hexa se ne sme uporabljati pri dojenčkih, ki so v preteklosti preboleli encefalopatijo (obolenje možganov) neznanega vzroka v sedmih dneh po prejemu cepiva proti oslovskemu kašlju.
• parts of Bordetella pertussis (B. pertussis, a bacterium that causes whooping cough); 
• dele bakterije Bordetella pertussis (B. pertussis, bakterije, ki povzroča oslovski kašelj);
An additional five studies looked at the effects of a booster vaccination with Infanrix hexa. 
V dodatnih petih študijah so proučevali učinke poživitvenega cepljenja z zdravilom Infanrix hexa.
The most common side effects with Infanrix hexa (seen in more than 1 in 10 doses of the vaccine) are swelling, pain and redness at the injection site, loss of appetite, fever of 38ºC or more, tiredness, abnormal crying, irritability and restlessness. 
Najpogostejši neželeni učinki zdravila Infanrix hexa (ki se lahko pojavijo pri več kot 1 odmerku od 10 odmerkov cepiva) so zatekanje, bolečina in pordelost na mestu injiciranja, izguba teka, povišana telesna temperatura, ki znaša 38 ºC ali več, utrujenost, neobičajen jok, razdražljivost in nemir.
For more information about treatment with Infanrix hexa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Infanrix hexa preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
A booster dose of Infanrix hexa or a similar vaccine must be given at least 6 months after the last dose of the initial course. 
Poživitveni odmerek cepiva Infanrix hexa ali podobnega cepiva je treba dati najmanj šest mesecev po zadnjem odmerku začetnega cepljenja.
• polysaccharides (sugars) from Haemophilus influenzae type b. 
• polisaharide (sladkorje) bakterije Haemophilus influenzae tipa b.
For practical information about using Infanrix hexa, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Infanrix hexa naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The safety of Infanrix hexa is similar to other vaccines used to prevent these conditions. 
Varnost zdravila Infanrix hexa je podobna varnosti drugih cepiv, ki se uporabljajo za preprečevanje teh bolezni.
Infanrix hexa is a vaccine that protects against a range of infections. 
Zdravilo Infanrix hexa je cepivo, ki ščiti proti različnim okužbam.
Why is Infanrix hexa approved? 
Zakaj je bilo zdravilo Infanrix hexa odobreno?
Subsequent injections should be given in different areas. 
Mesto injiciranja je treba pri naslednjih injekcijah zamenjati.
Infanrix hexa is given by deep injection into a muscle. 
Zdravilo Infanrix hexa se daje z injiciranjem globoko v mišico.
For the full list of side effects reported with Infanrix hexa, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Infanrix hexa, glejte navodilo za uporabo.
Infanrix hexa must not be used in infants who are hypersensitive (allergic) to any of the active substances, to any of the other ingredients of the vaccine, or to neomycin and polymyxin (antibiotics) and formaldehyde. 
Zdravilo Infanrix hexa se ne sme uporabljati pri dojenčkih, ki so preobčutljivi za (alergični na) katero koli zdravilno učinkovino, na katero koli drugo sestavino cepiva ali na neomicin in polimiksin (antibiotika) ter formaldehid.
Infanrix hexa contains the following active substances: 
Zdravilo Infanrix hexa vsebuje naslednje zdravilne učinkovine:
It is not intended to provide practical advice on how to use Infanrix hexa. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
What benefits of Infanrix hexa have been shown in studies? 
Kakšne koristi je zdravilo Infanrix hexa izkazalo v študijah?
What is Infanrix hexa and what is it used for? 
Kaj je zdravilo Infanrix hexa in za kaj se uporablja?
Results of the studies taken together showed that a course of injections with Infanrix hexa was as effective at producing protective levels of antibodies as giving separate vaccines containing the same active substances. 
Skupna analiza rezultatov študij je pokazala, da je bilo cepljenje z zdravilom Infanrix hexa enako učinkovito pri tvorjenju zaščitnih ravni protiteles kot dajanje ločenih cepiv, ki so vsebovala enake zdravilne učinkovine.
What is the risk associated with Infanrix hexa? 
Kakšna tveganja so povezana z zdravilom Infanrix hexa?
Infanrix hexa diphtheria (D), tetanus (T), pertussis (acellular, component) (PA), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed) 
Infanrix hexa konjugirano (adsorbirano) cepivo proti davici (D), tetanusu (T), oslovskemu kašlju (acelularno, komponentno) (PA), hepatitisu B (rDNA) (HBV), otroški paralizi (inaktivirano) (IPV) in bakteriji Haemophilus influenzae tipa b (Hib)
It must not be used in infants who have had an allergic reaction to a vaccine containing diphtheria, tetanus, pertussis, hepatitis B, polio or Hib. 
Ne sme se uporabljati pri dojenčkih, ki so v preteklosti imeli alergijsko reakcijo na cepivo, ki je vsebovalo komponente davice, tetanusa, oslovskega kašlja, hepatitisa B, otroške paralize ali Hib.
The effects of Infanrix hexa were compared with those of separate vaccines containing the same active substances. 
Učinke zdravila Infanrix hexa so primerjali z učinki ločenih cepiv, ki so vsebovala enake zdravilne učinkovine.
Over 3,000 of the children received a course of vaccination with Infanrix hexa. 
Z zdravilom Infanrix hexa je bilo cepljenih več kot 3 000 otrok.
Infanrix hexa is a vaccine used to protect babies and toddlers against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio) and diseases such as bacterial meningitis caused by the bacterium Haemophilus influenzae type b (Hib). 
Zdravilo Infanrix hexa je cepivo za zaščito dojenčkov in malčkov proti davici, tetanusu, oslovskemu kašlju, hepatitisu B, poliomielitisu (otroški paralizi) in boleznim, kot je bakterijski meningitis, ki ga povzroča bakterija Haemophilus influenzae tipa b (Hib).
Infanrix hexa is available as a powder and suspension that are made up into a suspension for injection. 
Zdravilo Infanrix hexa je na voljo kot prašek in raztopina za pripravo raztopine za injiciranje.
These studies showed that booster vaccinations with Infanrix hexa were as effective as giving separate vaccines containing the same active substances 1 month after the booster vaccination. 
V teh študijah so dokazali, da je bilo poživitveno cepljenje z zdravilom Infanrix hexa en mesec po poživitvenem cepljenju enako učinkovito kot dajanje ločenih cepiv, ki so vsebovala enake zdravilne učinkovine.
Infanrix hexa has been shown to be effective at producing protective levels of antibodies against diphtheria, tetanus, pertussis, hepatitis B virus, polioviruses, and Hib. 
Dokazali so, da je zdravilo Infanrix hexa učinkovito pri tvorjenju zaščitnih ravni protiteles proti davici, tetanusu, oslovskemu kašlju, virusu hepatitisa B, poliovirusom in Hib.
The immune system will then be able to produce antibodies more quickly when the person comes into contact with the bacteria or viruses. 
Ko bo oseba prišla v stik z bakterijami ali virusi, bo imunski sistem zato sposoben hitreje tvoriti protitelesa.
How is Infanrix hexa used? 
Kako se zdravilo Infanrix hexa uporablja?
Overall, between 95 and 100% of the children had antibodies to diphtheria, tetanus, pertussis, hepatitis B virus, polioviruses, and Hib, 1 month after the vaccination course. 
Po enem mesecu od cepljenja je na splošno med 95 in 100 % otrok razvilo protitelesa proti davici, tetanusu, oslovskemu kašlju, hepatitisu B, poliovirusom in Hib.
How does Infanrix hexa work? 
Kako zdravilo Infanrix hexa deluje?
5 x (1 x 10 ml) vials 
5 x (1 x 10 ml) vial
EU number Invented name Strength Pharmaceutical form Route of administration Packaging Content (concentration) 
Lastniško ime Jakost Farmacevtska obllika
You can do this by holding them in your hands until they feel as warm as your hands. 
To lahko naredite tako, da ju držite v dlaneh, dokler nista enako topli kot vaše dlani.
Your doctor might change the dose. 
Zdravnik vam lahko spremeni odmerek.
When to treat yourself 
Kdaj se morate zdraviti
Positive status indicates at least one positive test at any admission. 
Pozitivni status pomeni vsaj en pozitivni test pri katerem koli sprejemu v bolnišnico.
Always wash your hands and ensure that the area around you is clean. 
Vedno si umijte roke in poskrbite, da je vaša okolica čista.
It must be colourless. 
Biti mora brezbarvna.
Monitoring of treatment - laboratory tests 
Nadziranje zdravljenja - laboratorijske preiskave
Two dosing regimens can be recommended: 
Priporočiti je mogoče dve shemi odmerjanja:
This reduces the need for hospitalisation and days absent from work and school. 
To zmanjša potrebo po sprejemu v bolnišnico in število dni odsotnosti z dela ali iz šole.